Skip to main content

Advertisement

Log in

Effect of the modulation of leucine zipper tumor suppressor 2 expression on proliferation of various cancer cells functions as a tumor suppressor

  • Published:
Molecular and Cellular Biochemistry Aims and scope Submit manuscript

An Erratum to this article was published on 06 December 2011

Abstract

β-catenin is a component of the adhesion complex linking cadherin and actin cytoskeleton, as well as a major mediator of the Wnt pathway, which is a critical signal cascade regulating embryonic development, cell polarity, carcinogenesis, and stem cell function. NF-κB functions as a key regulator of immune responses and apoptosis, and mutations in NF-κB signaling can lead to immune diseases and cancers. We previously showed that NF-κB-mediated modulation of β-catenin/Tcf signaling is mediated by leucine zipper tumor suppressor 2 (Lzts2) and that lzts2 expression is differentially regulated in various cancer cells. Its functional significances, however, are poorly understood. We showed that NF-κB-induced modulation of β-catenin/Tcf pathway is regulated by lzts2 expression in mesenchymal stem cells (MSCs) and several cancer cells, and that NF-κB-induced lzts2 expression is differentially regulated among cancer cell types. Here, using a promoter–reporter assay and EMSA, we demonstrate that NF-κB regulates lzts2 transcription by directly binding to the lzts2 promoter, and that NF-κB-induced lzts2 transcription differs by cell types. Modulation of lzts2 expression by lentiviral techniques affected proliferation and tumorigenicity of several cancer cell lines such as breast, colon, prostate cancer, and glioma, but did not affect cisplatin sensitivity or cell migration. Our data indicate that lzts2 expression is transcriptionally regulated by NF-κB activities, and the modulation of lzts2 expression affects cell proliferation and tumor growth through the Wnt/β-catenin pathway in various cancer cell lines.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6
Fig. 7
Fig. 8

Similar content being viewed by others

References

  1. Logan CY, Nusse R (2004) The Wnt signaling pathway in development and disease. Annu Rev Cell Dev Biol 20:781–810

    Article  PubMed  CAS  Google Scholar 

  2. MacDonald BT, Tamai K, He X (2009) Wnt/beta-catenin signaling: components, mechanisms, and diseases. Dev Cell 17:9–26

    Article  PubMed  CAS  Google Scholar 

  3. Bian YS, Osterheld MC, Bosman FT, Fontolliet C, Benhattar J (2000) Nuclear accumulation of beta-catenin is a common and early event during neoplastic progression of Barrett esophagus. Am J Clin Pathol 114:583–590

    Article  PubMed  CAS  Google Scholar 

  4. Eberhart CG, Tihan T, Burger PC (2000) Nuclear localization and mutation of beta-catenin in medulloblastomas. J Neuropathol Exp Neurol 59:333–337

    PubMed  CAS  Google Scholar 

  5. Li Q, Verma IM (2002) NF-κB regulation in the immune system. Nat Rev Immunol 2:725–734

    Article  PubMed  CAS  Google Scholar 

  6. Lin A, Karin M (2003) NF-κB in cancer: a marked target. Semin Cancer Biol 13:107–114

    Article  PubMed  CAS  Google Scholar 

  7. Mayo MW, Baldwin AS (2000) The transcription factor NF-κB: control of oncogenesis and cancer therapy resistance. Biochim Biophys Acta 1470:M55–M62

    PubMed  CAS  Google Scholar 

  8. Prasad S, Ravindran J, Aggarwal BB (2010) NF-kappaB and cancer: how intimate is this relationship. Mol Cell Biochem 336:25–37

    Article  PubMed  CAS  Google Scholar 

  9. Chang AA, Van Waes C (2005) Nuclear factor-kappaB as a common target and activator of oncogenes in head and neck squamous cell carcinoma. Adv Otorhinolaryngol 62:92–102

    PubMed  CAS  Google Scholar 

  10. Pepper C, Hewamana S, Brennan P, Fegan C (2009) NF-kappaB as a prognostic marker and therapeutic target in chronic lymphocytic leukemia. Future Oncol 5:1027–1237

    Article  PubMed  CAS  Google Scholar 

  11. Deng J et al (2002) Beta-catenin interacts with and inhibits NF-kappa B in human colon and breast cancer. Cancer Cell 2:323–334

    Article  PubMed  CAS  Google Scholar 

  12. Polakis P (2000) Wnt signaling and cancer. Genes Dev 14:1837–1851

    PubMed  CAS  Google Scholar 

  13. Hoeflich KP, Luo J, Rubie EA, Tsao MS, Jin O, Woodgett JR (2000) Requirement for glycogen synthase kinase-3beta in cell survival and NF-kappaB activation. Nature 406:86–90

    Article  PubMed  CAS  Google Scholar 

  14. Wang X, Adhikari N, Li Q, Guan Z, Hall JL (2004) The role of [beta]-transducin repeat containing protein ([beta]-TrCP) in the regulation of NF-[kappa]B in vascular smooth muscle cells. Arterioscler Thromb Vasc 24:85–90

    Article  Google Scholar 

  15. Cho HH, Joo HJ, Song JS, Bae YC, Jung JS (2007) Crossregulation of β-catenin/Tcf pathway by NF-κB is mediated by lzts2 in human adipose tissue-derived mesenchymal stem cells. Biochim Biophys Acta 26:8857–8867

    Google Scholar 

  16. Thyssen G, Li TH, Lehmann L, Zhuo M, Sharma M, Sun Z (2006) LZTS2 is a novel beta-catenin-interacting protein and regulates the nuclear export of beta-catenin. Mol Cell Biol 26:8857–8867

    Article  PubMed  CAS  Google Scholar 

  17. Cho HH, Song JS, Yu JM, Yu SS, Choi SJ, Kim DH, Jung JS (2008) Differential effect of NF-kappaB activity on beta-catenin/Tcf pathway in various cancer cells. FEBS Lett 582:616–622

    Article  PubMed  CAS  Google Scholar 

  18. Bours V, Bentires-Alj M, Hellin AC, Viatour P, Robe P, Delhalle S, Benoit V, Merville MP (2000) Nuclear factor-kappa B, cancer, and apoptosis. Biochem Pharmacol 60:1085–1089

    Article  PubMed  CAS  Google Scholar 

  19. Zhu J, He F, Hu S, Yu J (2008) On the nature of human housekeeping genes. Trends Genet 24:481–484

    Article  PubMed  CAS  Google Scholar 

  20. Goodrich JA, Cutler G, Tjian R (1996) Contacts in context: promoter specificity and macromolecular interactions in transcription. Cell 84:825–830

    Article  PubMed  CAS  Google Scholar 

  21. Janknecht R, Hunter T (1996) Transcription. A growing coactivator network. Nature 383:22–23

    Article  PubMed  CAS  Google Scholar 

  22. Sun H, Chung WC, Ryu SH, Ju Z, Tran HT, Kim E, Kurie JM, Koo JS (2008) Cyclic AMP-responsive element binding protein- and nuclear factor-{kappa}B-regulated CXC chemokine gene expression in lung carcinogenesis. Cancer Prev Res 1:316–328

    Article  CAS  Google Scholar 

  23. Yabe T, Sanagi T, Schwartz JP, Yamada H (2005) Pigment epithelium-derived factor induces pro-inflammatory genes in neonatal astrocytes through activation of NF-kappa B and CREB. Glia 50:223–234

    Article  PubMed  Google Scholar 

  24. Parry GC, Mackman N (1997) Role of cyclic AMP response element-binding protein in cyclic AMP inhibition of NF-kappaB-mediated transcription. J Immunol 159:5450–5456

    PubMed  CAS  Google Scholar 

  25. Delgado M, Munoz-Elias EJ, Kan Y, Gozes I, Fridkin M, Brenneman DE, Gomariz RP, Ganea D (1998) Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide inhibit tumor necrosis factor alpha transcriptional activation by regulating nuclear factor-kB and cAMP response element-binding protein/c-Jun. J Biol Chem 273:31427–31436

    Article  PubMed  CAS  Google Scholar 

  26. López-Knowles E, Zardawi SJ, McNeil CM, Millar EK, Crea P, Musgrove EA, Sutherland RL, O’Toole SA (2010) Cytoplasmic localization of beta-catenin is a marker of poor outcome in breast cancer patients. Cancer Epidemiol Biomark Prev 19:301–309

    Article  Google Scholar 

  27. Sethi G, Sung B, Aggarwal BB (2008) Nuclear factor-kappaB activation: from bench to bedside. Exp Biol Med (Maywood) 233:21–31

    Article  CAS  Google Scholar 

  28. Nakanishi C, Toi M (2005) Nuclear factor-kappaB inhibitors as sensitizers to anticancer drugs. Nat Rev Cancer 5:297–309

    Article  PubMed  CAS  Google Scholar 

  29. Wang CY, Mayo MW, Baldwin AS Jr (1996) TNF- and cancer therapy-induced apoptosis: potentiation by inhibition of NF-kappaB. Science 274:784–787

    Article  PubMed  CAS  Google Scholar 

  30. Ji D, Deeds SL, Weinstein EJ (2007) A screen of shRNAs targeting tumor suppressor genes to identify factors involved in A549 paclitaxel sensitivity. Oncol Rep 18:1499–1505

    PubMed  CAS  Google Scholar 

  31. Saldanha G, Ghura V, Potter L, Fletcher A (2004) Nuclear β-catenin in basal cell carcinoma correlates with increased proliferation. Br J Dermatol 151:157–164

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgments

This study was supported by a grant (20080463000) of National Research Foundation (NRF).

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Jin Sup Jung.

Additional information

Jong Myung Kim, Ji Sun Song are the two authors contributed equally to this study.

An erratum to this article can be found at http://dx.doi.org/10.1007/s11010-011-1177-7

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kim, J.M., Song, J.S., Cho, H.H. et al. Effect of the modulation of leucine zipper tumor suppressor 2 expression on proliferation of various cancer cells functions as a tumor suppressor. Mol Cell Biochem 346, 125–136 (2011). https://doi.org/10.1007/s11010-010-0599-y

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11010-010-0599-y

Keywords

Navigation